Shares of Virtuix Holdings (VTIX) plunged to $4.56 on April 23 — a -13.4% single-day drop — extending a brutal two-day selloff that has erased nearly a third of the stock's value since April 21. The catalyst: SEC filings revealing that CEO Jan Goetgeluk has sold shares on nearly every trading day this month, rattling investors in a company that only went public in January.

  • The CEO Has Sold Over 50,000 Shares in Three Weeks — and Counting. Goetgeluk sold 10,272 shares on April 6–7 , 14,423 shares on April 8–9 , 10,555 shares on April 13–14 , another 17,508 shares on April 15–16 — totaling roughly 52,758 shares at prices between $5.95 and $6.43. All sales were executed under a pre-established Rule 10b5-1 trading plan — a pre-set schedule that insiders set up in advance to avoid accusations of trading on private information. That legal cover hasn't stopped the market from punishing the stock. Following the latest sales, Goetgeluk still holds roughly 4.45 million shares , so the disposals are tiny relative to his stake — but the optics for a three-month-old public company are poisonous.

  • A $3.6 Million Revenue Company Trading at a Premium Valuation. Fiscal 2025 revenue was just $3.59 million, up 49% year-over-year , while losses widened to $14.65 million . Trailing revenue sits at roughly $4.5 million against a gross margin of just 22% . Even at today's beaten-down price, the stock trades at over 30x trailing sales — a steep multiple for a hardware company burning roughly $600,000 per month in cash . The entire bull case rests on ramping production capacity that could generate $100 million in annual revenue — but that's a target, not a reality.

  • Analysts Are Split, Leaning Cautious. Wall Street Zen downgraded Virtuix to a "sell" on April 4 , while Zacks upgraded it to "hold."

The latest 10-Q showed continuing losses and going-concern language — auditor-speak signaling doubt about the company's ability to survive without raising more money.

  • The VR Treadmill's $3,500 Price Tag Limits the Buyer Pool. The product's $3,495 price remains a high barrier for the average consumer , making defense contracts and commercial partnerships critical. A recent Navy research agreement and a Meta partnership are promising, but neither has moved the revenue needle yet. Until orders materially accelerate, the CEO selling shares — pre-planned or not — will dominate the narrative.